Changes of chronic hepatitis C virus anti-core and envelope antibodies by interferon therapy

International Hepatology Communications Pub Date : 1996-10-01 DOI:10.1016/0928-4346(96)00312-X

Fumihiko Komine , Mituhiko Moriyama , Nakanobu Hayashi , Toshikazu Uchida , Toshio Shikata , Yasuyuki Arakawa

{"title":"Changes of chronic hepatitis C virus anti-core and envelope antibodies by interferon therapy","authors":"Fumihiko Komine , Mituhiko Moriyama , Nakanobu Hayashi , Toshikazu Uchida , Toshio Shikata , Yasuyuki Arakawa","doi":"10.1016/0928-4346(96)00312-X","DOIUrl":null,"url":null,"abstract":"<div><p>We measured the levels of three antibodies against core (JCC-2), E1 (E1–5), and <span><math><mtext>E2</mtext><mtext>NS1</mtext></math></span> (E2-1) hepatitis C virus (HCV) before and after interferon (IFN) therapy in 22 patients with chronic hepatitis C and assessed the relationship between the changes in these antibody titers and the response to IFN. The titers of serum JCC-2 and E2-1 antibodies before the IFN therapy did not show any significant relationship with IFN efficacy. In contrast, the titer of E1–5 antibody was significantly lower in the complete responder (CR) group than in the non-responder (NR) group. The JCC-2 antibody titer of the CR group to IFN therapy showed a significant decrease immediately, at 6 months and 1 year after the completion of IFN administration. However, that of the NR group either did not change or rose again 6 months or 1 year after therapy following an immediate short-term decrease. Thus the E1–5 antibody titer before IFN therapy and the JCC-2 antibody titer during IFN therapy seems to be a good indicator of IFN efficacy. In contrast, the E2-1 antibody did not correlate with IFN efficacy.</p></div>","PeriodicalId":13746,"journal":{"name":"International Hepatology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0928-4346(96)00312-X","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Hepatology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/092843469600312X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

We measured the levels of three antibodies against core (JCC-2), E1 (E1–5), and $E2 NS1$ (E2-1) hepatitis C virus (HCV) before and after interferon (IFN) therapy in 22 patients with chronic hepatitis C and assessed the relationship between the changes in these antibody titers and the response to IFN. The titers of serum JCC-2 and E2-1 antibodies before the IFN therapy did not show any significant relationship with IFN efficacy. In contrast, the titer of E1–5 antibody was significantly lower in the complete responder (CR) group than in the non-responder (NR) group. The JCC-2 antibody titer of the CR group to IFN therapy showed a significant decrease immediately, at 6 months and 1 year after the completion of IFN administration. However, that of the NR group either did not change or rose again 6 months or 1 year after therapy following an immediate short-term decrease. Thus the E1–5 antibody titer before IFN therapy and the JCC-2 antibody titer during IFN therapy seems to be a good indicator of IFN efficacy. In contrast, the E2-1 antibody did not correlate with IFN efficacy.

查看原文本刊更多论文

干扰素治疗对慢性丙型肝炎病毒抗核心和包膜抗体的影响

我们测量了22例慢性丙型肝炎患者在干扰素(IFN)治疗前后抗丙型肝炎病毒(HCV)的三种抗体(JCC-2)、E1 (E1 - 5)和E2NS1 (E2-1)的水平，并评估了这些抗体滴度的变化与对IFN的反应之间的关系。IFN治疗前血清JCC-2和E2-1抗体滴度与IFN疗效无显著关系。完全应答(CR)组e2 - 5抗体滴度明显低于无应答(NR)组。在IFN给药结束后6个月和1年，CR组对IFN治疗的JCC-2抗体滴度立即显著下降。然而，NR组在治疗后6个月或1年没有改变或在短期立即下降后再次上升。因此，IFN治疗前的E1-5抗体滴度和IFN治疗期间的JCC-2抗体滴度似乎是IFN疗效的良好指标。相反，E2-1抗体与IFN的疗效无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Hepatology Communications

自引率

0.00%

发文量